Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)
16 sept. 2019 16h15 HE
|
Aclaris Therapeutics, Inc.
Highly statistically significant results at the primary endpoint - statistical significance seen as early as Day 29Highly statistically significant results on all secondary efficacy endpointsWART-302...
Aclaris Therapeutics Announces New Strategic Direction
05 sept. 2019 08h30 HE
|
Aclaris Therapeutics, Inc.
Completion of Strategic Review and Refocusing of Resources on Immuno-Inflammatory Development PipelineActively Seeking a Commercialization Partner for RHOFADE® (oxymetazoline hydrochloride) cream,...
Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments
08 août 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
Undertaking strategic review of commercial and R&D assetsIND for ATI-450, an investigational compound and oral MK2 inhibitor, allowed by the FDA in May 2019, and first patient dosed in Phase 1...
Aclaris Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019
01 août 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint
30 juil. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
ATI-501 achieved statistically significant improvement over placebo in several measures of hair growth, including the primary endpoint and certain secondary endpoints of the trial.ATI-501 was...
Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering RHOFADE® (Oxymetazoline Hydrochloride) Cream, 1%
09 juil. 2019 07h00 HE
|
Aclaris Therapeutics, Inc.
Issuance of U.S. Patent No. 10,335,391 Further Strengthens Aclaris’ RHOFADE Patent Portfolio WAYNE, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led...
Aclaris Therapeutics Announces Appointment of Maxine Gowen to Board of Directors
03 juil. 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., July 03, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-502 Topical in Patients with Alopecia Areata Did Not Meet Endpoints
26 juin 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
ATI-502 did not achieve statistical superiority at the primary or secondary endpoints due to high rates of disease resolution in vehicle-treated patients WAYNE, Pa., June 26, 2019 (GLOBE NEWSWIRE)...
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)
17 juin 2019 06h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...
Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference
14 juin 2019 16h01 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 14, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today...